In this article, ACROBiosystems discusses how the complement cascade and it's various components could potentially be leveraged for therapeutic potential in COVID-19, cancer and general inflammation.

Researchers investigated the complement component 1q (C1q) binding and subsequent complement activation by neutralizing antibodies (nAbs) produced following COVID-19 vaccination.

To investigate, first author Scott-Hewitt isolated synaptosomes from wild-type mice and immunoprecipitated C1q from them, checking to see what else came along for the ride. Unexpectedly, C1q from year ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Annexon Biosciences, a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement ...

Lee K. Tan, Robert J. Shopes, Vernon T. Oi, Sherie L. Morrison, Influence of the Hinge Region on Complement Activation, C1q Binding, and Segmental Flexibility in Chimeric Human Immunoglobulins, ...